U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. IntegraDose Compounding Services, LLC Issues Voluntary Nationwide Recall of Cefazolin Injection Products Due to a Lack of Sterility Assurance
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

IntegraDose Compounding Services, LLC Issues Voluntary Nationwide Recall of Cefazolin Injection Products Due to a Lack of Sterility Assurance

This recall has been completed and FDA has terminated this recall.

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement View Product Photos

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Pharmaceutical Quality
Reason for Announcement:
Recall Reason Description
Lack of sterility assurance.
Company Name:
IntegraDose Compounding Services, LLC
Brand Name:
Brand Name(s)
IntegraDose Compounding Services, LLC
Product Description:
Product Description
Cefazolin

Company Announcement

Minneapolis, Minnesota, IntegraDose Compounding Services is voluntarily recalling nine lots, listed in the table below, of cefazolin 2 gram in 20 mL syringe for injection and two lots of cefazolin 3 gram in 100 mL 0.9% sodium chloride bag for injection due to a lack of sterility assurance resulting from compounding in a newly installed biologic safety cabinet without completing dynamic smoke study testing.

Product

NDC

Lot

Exp

Cefazolin 2 gram in 20 mL syringe for injection

 

71139-7087-1 20210803CEF-1 09/17/2021
71139-7087-1 20210805CEF-3 09/19/2021
71139-7087-1 20210806CEF-1 09/20/2021
71139-7087-1 20210806CEF-2 09/20/2021
71139-7087-1 20210809CEF-1 09/23/2021
71139-7087-1 20210809CEF-2 09/23/2021
71139-7087-1 20210810CEF-1 09/24/2021
71139-7087-1 20210811CEF-1 09/25/2021
71139-7087-1 20210812CEF-1 09/26/2021
Cefazolin 3 gram in 100 mL 0.9% sodium chloride bag for injection 71139-7053-1 20210722CEF-2 09/20/2021
71139-7053-1 20210728CEF-1 09/26/2021

Intravenous administration of a non-sterile drug could result in serious infections ranging from fever, chills, and malaise, to severe adverse events such as septicemia, bacterial meningitides and wound infection which may be life-threatening. The possibility of a breach in sterility assurance in distributed product, while not confirmed, cannot be eliminated. No batches of product have been identified as containing microorganisms. To date, IntegraDose Compounding Services has not received reports of any adverse events associated with this issue for these lots.

Cefazolin is an antibiotic and the products are packaged in zip-locking bags containing ten units. The lots were distributed nationwide in the USA to hospitals from 8/12/21 to 9/15/21. IntegraDose Compounding Services has initiated an investigation to determine the root cause and corrective and preventative actions.

IntegraDose Compounding Services has notified its direct customers via a recall letter and is arranging for impacted product to be returned. Anyone with an existing inventory of the recalled lots should stop use and distribution and quarantine immediately.

Consumers with questions regarding this recall can contact IntegraDose Compounding Services by phone at (612-672-5216) or e-mail (celse1@fairview.org) on Monday - Friday, 8:00 AM – 4:00 PM CDT. 

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


Company Contact Information

Consumers:
IntegraDose
612-672-5216
celse1@fairview.org
Media:
Craig Else, Director/COO
612-672-5216
craig.else@integradose.org

Product Photos

Back to Top